Skip to main content

Advertisement

Table 1 Clinical characteristics of study population and inter-group difference significance levels (Mann–Whitney)

From: The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology

  Insulin non-resistant (n = 30) Insulin resistant (n = 28) Significance (p value)
Age (years) 62 ± 5 (55–69) 63 ± 4 (55–70) 0.33
MMSE, total score 29 ± 1 (25–30) 29 ± 1 (25–30) 0.44
BMI (kg/m2) 28.9 ± 1.8 (27.1–35.2) 30.1 ± 2.3 (27.1–36.0) 0.02*
APOE genotype (count, % ε4+) 13 43.3% 10 35.7% 0.56
Matsuda 9.1 ± 3.1 (6.4–17.2) 2.1 ± 0.3 (1.5–2.5) 0.00*
P-glucose (mmol/l) 5.7 ± 0.4 (4.8–6.7) 6.0 ± 0.6 (5.1–7.4) 0.12
P-insulin (mU/l), LIAISON 7.7 ± 3.8 (1.5–19.5) 19.6 ± 8.1 (8.0–43.2) 0.00*
P-insulin (mU/l), ELISA 5.4 ± 2.5 (1.4–12.3) 13.9 ± 6.3 (5.9–31.6) 0.00*
CSF insulin (mU/l), ELISA 0.15 ± 0.12 (0.10–0.64) 0.22 ± 0.15 (0.1–0.7) 0.00*
Aβ-42 (pg/ml), Fujirebio 856 ± 195 (530–1256) 888 ± 204 (531–1313) 0.59
T-tau (pg/ml), Fujirebio 256 ± 122 (107–670) 283 ± 110 (144–694) 0.16
P-tau (pg/ml), Fujirebio 44 ± 18 (20–105) 52 ± 28 (25–183) 0.10
CSF Aβ/tau 3.75 ± 1.0 (0.87-6.12) 3.38 ± 0.9 (1.31-5.04) 0.13
  1. Data presented as mean ± SD (minimum–maximum) or as count (percentage) for the categorical variable (APOE ε4 status)
  2. MMSE Mini-Mental State Examination, BMI body mass index, APOE apolipoprotein E, ELISA enzyme-linked immunosorbent assay, CSF cerebrospinal fluid, amyloid beta, T-tau total tau, P-tau tau phosphorylated at the Thr181 epitope
  3. *Significant at p < 0.05